Overview

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Status:
Active, not recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies the side effects and best dose of gemcitabine, bendamustine, and nivolumab when given together and to see how well they work in treating patients with classic Hodgkin lymphoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as gemcitabine and bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving gemcitabine, bendamustine, and nivolumab may work better in treating patients with classic Hodgkin lymphoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Emory University

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Bendamustine Hydrochloride
Gemcitabine
Nivolumab